Related Experiment Video
Updated: Nov 2, 2025
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Commercialized Hybrid Closed-Loop System (Minimed Medtronic 670G) Results During Pregnancy
Jesús Moreno-Fernández1, José Alberto García-Seco1
1Endocrinology and Nutrition Department, Ciudad Real University Hospital, Ciudad Real, Spain.
Objective:
Hybrid closed-loop (HCL) devices can achieve tight glycemic control but are rarely used in pregnancy, which remains an off-label indication. We present a case of a pregnant patient with type 1 diabetes mellitus (T1DM) who used the Medtronic MiniMed 670G HCL system.
Methods:
MiniMed 670G includes an advanced automode option (HCL therapy), which our patient used from the first trimester to the end of the pregnancy.
Results:
An unplanned pregnancy was detected in the T1DM patient, with a glycated hemoglobin level of 8.7 mmol/L (7.1%). The patient started sensor-augmented pump therapy at week 13. Subsequently, she entered automode (HCL) at week 16. The time in range (3.7-7.8 mmol/mol, 63-140 mg/dL) increased from 46.8% to 51.3% after HCL initiation. The glycated hemoglobin level remained close to 48 mmol/mol (6.5%) until the end of the pregnancy. Furthermore, the time under range (<3.7 mmol/mol, <63 mg/dL) remained below the optimal 4% level during the gestation. Finally, a healthy male baby was born at week 37. No safety events were recorded.
Conclusion:
This case represents the successful off-label use of HCL during pregnancy in a patient with T1DM.
